Potential Mutagenic Impurity (GTI) Assessments
Using a range of different software tools, Arcinova has the necessary expertise to assess the mutagenic potential of impurities and degradation products from drug substance and drug product manufacture, which is required for successful regulatory submissions and to comply with ICH M7 guidance,
Some impurities, which are highly reactive because of their structure, have the potential to interact with DNA.
MHRA SymposiumThe 2018 MHRA Symposium will be attended by John McRoberts, Head of QA.
MHRA SymposiumDates: 20th NovemberLocation: London, UK
AAPS: PharmSci360This years' PharmSci360 conference will be attended by Masha Kononov, Senior Director Emerging Biotech US.
AAPS: PharmSci360Dates: 4th - 7th NovemberLocation: Washington DC, US
Bio-Europe 2018Bio-Europe autumn conference will be attended by Nathalie Huther, Business Development Manager Europe.
Bio-Europe 2018Dates: 5th - 7th NovemberLocation: Copenhagen, Denmark